Cheng-Kai Kao to Anticoagulants
This is a "connection" page, showing publications Cheng-Kai Kao has written about Anticoagulants.
Connection Strength
0.291
-
Comparison of Fatal or Irreversible Events With Extended-Duration Betrixaban Versus Standard Dose Enoxaparin in Acutely Ill Medical Patients: An APEX Trial Substudy. J Am Heart Assoc. 2017 Jul 11; 6(7).
Score: 0.103
-
Extended-Duration Betrixaban Reduces the Risk of Stroke Versus Standard-Dose Enoxaparin Among Hospitalized Medically Ill Patients: An APEX Trial Substudy (Acute Medically Ill Venous Thromboembolism Prevention With Extended Duration Betrixaban). Circulation. 2017 02 14; 135(7):648-655.
Score: 0.098
-
Neurologic complication after a roller coaster ride. Am J Emerg Med. 2012 Jan; 30(1):249.e5-7.
Score: 0.065
-
The safety and efficacy of full- versus reduced-dose betrixaban in the Acute Medically Ill VTE (Venous Thromboembolism) Prevention With Extended-Duration Betrixaban (APEX) trial. Am Heart J. 2017 Mar; 185:93-100.
Score: 0.025